Journal
Journal for Immunotherapy of Cancer
Publication Date
7-25-2025
Volume
13
Issue
7
First Page
e011651
Document Type
Open Access Publication
DOI
10.1136/jitc-2025-011651
Rights and Permissions
Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. J Immunother Cancer. 2025 Jul 25;13(7):e011651. doi: 10.1136/jitc-2025-011651. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Milhem, Mohammed M; Ansstas, George; and et al., "Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors." Journal for Immunotherapy of Cancer. 13, 7. e011651 (2025).
https://digitalcommons.wustl.edu/oa_4/5657
Additional Links
Supplemental material is available for this article at publisher site.
